Publications by authors named "Jaydeepbhai Patel"
Article Synopsis
- The 5-year relative survival rate for pancreatic cancer is the lowest among all cancers at only 13%, with KRAS gene mutations found in about 90% of patients.
- Advances in genomic testing allow for the identification of genetic alterations in patients without the KRAS mutation, known as KRAS wild-type, which can guide targeted therapy.
- These alterations include a range of genetic changes and may present opportunities for tailored treatment approaches through clinical trials or existing drugs, with notable efficacy shown in some studies.
Background: Atezolizumab is superior to docetaxel for patients with advanced non-small-cell lung cancer (NSCLC) who are pretreated with platinum-based chemotherapy based on the POPLAR and OAK trials. However, patients who received prior immunotherapy were excluded from these trials. The standard of care second-line therapy for these patients remains to be docetaxel with or without ramucirumab.
View Article and Find Full Text PDF